Loading...
•
Apr 01, 2023
Haemonetics Q4 2023 Earnings Report
Haemonetics reported Q4 2023 earnings with revenue increase and provided fiscal 2024 guidance.
Key Takeaways
Haemonetics Corporation reported a 14.9% increase in revenue for the fourth quarter of fiscal year 2023, reaching $304.4 million. Earnings per diluted share were $0.57, and adjusted earnings per diluted share were $0.77. The company provided fiscal year 2024 revenue and earnings guidance.
Q4 fiscal 2023 revenue increased by 14.9% to $304.4 million.
Earnings per diluted share for Q4 fiscal 2023 were $0.57, compared to $0.19 in the same period last year.
Adjusted earnings per diluted share for Q4 fiscal 2023 were $0.77, up from $0.65 in the prior year.
The company issued its fiscal 2024 GAAP total revenue and organic revenue growth guidance.
Revenue by Segment
Forward Guidance
The Company issued its fiscal 2024 GAAP total revenue and organic revenue growth guidance as follows: Total CompanyFY 2024Reported4 - 7%Currency impact(1)%Organic5 - 8%Business unit organic revenueFY 2024Plasma revenue3 - 6%Blood Center revenue(2) - 0%Hospital revenue16 - 18% Additionally, the Company issued its adjusted operating margin, adjusted earnings per diluted share and free cash flow before restructuring and restructuring related costs guidance as follows: Adjusted operating margin20 - 21%Adjusted earnings per diluted share$3.45 - $3.75Free cash flow, before restructuring and restructuring related costs$80M - $100M
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...